

Corporate Satellite Symposium

Luncheon Symposium: Supported by Biocompatibles UK Ltd



Thursday, 1 July 2010

12:45 - 14:15

Level 1, Rooms 111 - 112

Latest clinical and pathological results of drug-eluting beads in the management of metastatic colorectal and hepatocellular carcinoma

Chair: *Eric Van Cutsem*
Leven, Belgium

LC Bead™, Irinotecan therapy of liver metastases from colon cancer with concomitant FOLFOX 6 and anti-angiogenic therapy

Robert Martin
Kentucky, United States

Neoadjuvant DC bead® (Drug-eluting bead) Irinotecan (DEBIRI) for resectable colorectal liver metastases

Graeme Poston
Liverpool, United Kingdom

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy in combination with anti EGFR treatment in patient with refractory colorectal cancer and predominant liver metastases

Dirk Arnold
Halle, Germany